日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

在 RELATIVITY-047 研究中,利用生物标志物分析揭示晚期黑色素瘤患者中 Relatlimab 特异性生物学

Lipson, Evan J; Dolfi, Sonia; Tang, Hao; Tawbi, Hussein A; Medina-Soto, Francisco; Castillo Gutiérrez, Erika; Rutkowski, Piotr; Gogas, Helen; Murillo, Emilio; Ascierto, Paolo A; Desai, Keyur; Maio, Michele; Demers, Korey; Mazzei, Antonella; Keidel, Sarah; Miller-Moslin, Karen; Yu, Jia Xin; Hodi, F Stephen; Schadendorf, Dirk; Long, Georgina V; Garnett-Benson, Charlie

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis

奥扎尼莫德与血清素能抗抑郁药同时用于溃疡性结肠炎或复发性多发性硬化症患者

Regueiro, Miguel; Siegmund, Britta; Horst, Sara; Moslin, Ryan; Charles, Lorna; Petersen, AnnKatrin; Tatosian, Daniel; Wu, Hsiuanlin; Lawlor, Garrett; Fischer, Monika; D'Haens, Geert; Colombel, Jean-Frederic

Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

基于模型的纳武利尤单抗和瑞拉利单抗新型固定剂量组合在成人和青少年实体瘤患者中的临床药理学特征

Zhao, Yue; Hu, Zheyi; Bathena, Sai Praneeth; Keidel, Sarah; Miller-Moslin, Karen; Statkevich, Paul; Bello, Akintunde; Roy, Amit; Suryawanshi, Satyendra

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

纳武利尤单抗联合伊匹木单抗对比 EXTREME 方案作为复发/转移性头颈部鳞状细胞癌一线治疗:CheckMate 651 研究的最终结果

Haddad, Robert I; Harrington, Kevin; Tahara, Makoto; Ferris, Robert L; Gillison, Maura; Fayette, Jerome; Daste, Amaury; Koralewski, Piotr; Zurawski, Bogdan; Taberna, Miren; Saba, Nabil F; Mak, Milena; Kawecki, Andrzej; Girotto, Gustavo; Alvarez Avitia, Miguel Angel; Even, Caroline; Toledo, Joaquin Gabriel Reinoso; Guminski, Alexander; Müller-Richter, Urs; Kiyota, Naomi; Roberts, Mustimbo; Khan, Tariq Aziz; Miller-Moslin, Karen; Wei, Li; Argiris, Athanassios

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial

纳武利尤单抗联合伊匹木单抗与纳武利尤单抗单药治疗复发或转移性头颈部鳞状细胞癌的疗效和安全性:CheckMate 714 II期随机临床试验

Harrington, Kevin J; Ferris, Robert L; Gillison, Maura; Tahara, Makoto; Argiris, Athanasios; Fayette, Jérôme; Schenker, Michael; Bratland, Åse; Walker, John W T; Grell, Peter; Even, Caroline; Chung, Christine H; Redman, Rebecca; Coutte, Alexandre; Salas, Sébastien; Grant, Cliona; de Azevedo, Sergio; Soulières, Denis; Hansen, Aaron R; Wei, Li; Khan, Tariq Aziz; Miller-Moslin, Karen; Roberts, Mustimbo; Haddad, Robert

Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling

鉴定咪唑并[1,2-b]哒嗪类TYK2假激酶配体为TYK2信号传导的强效选择性变构抑制剂

Moslin, R; Gardner, D; Santella, J; Zhang, Y; Duncia, J V; Liu, C; Lin, J; Tokarski, J S; Strnad, J; Pedicord, D; Chen, J; Blat, Y; Zupa-Fernandez, A; Cheng, L; Sun, H; Chaudhry, C; Huang, C; D'Arienzo, C; Sack, J S; Muckelbauer, J K; Chang, C; Tredup, J; Xie, D; Aranibar, N; Burke, J R; Carter, P H; Weinstein, D S

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

发现一种强效且选择性的平滑拮抗剂 NVP-LDE225

Shifeng Pan, Xu Wu, Jiqing Jiang, Wenqi Gao, Yongqin Wan, Dai Cheng, Dong Han, Jun Liu, Nathan P Englund, Yan Wang, Stefan Peukert, Karen Miller-Moslin, Jing Yuan, Ribo Guo, Melissa Matsumoto, Anthony Vattay, Yun Jiang, Jeffrey Tsao, Fangxian Sun, AnneMarie C Pferdekamper, Stephanie Dodd, Tove Tuntl

SmI2-promoted Reformatsky-type coupling reactions in exceptionally hindered contexts

在极度受限的条件下,SmI2促进的Reformatsky型偶联反应

Sparling, Brian A; Moslin, Ryan M; Jamison, Timothy F